欢迎来到天天文库
浏览记录
ID:53732006
大小:288.64 KB
页数:3页
时间:2020-04-20
《小剂量TP方案联合三维适形放疗治疗老年局部晚期非小细胞肺癌的临床观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在应用文档-天天文库。
1、小剂量TP方案联合三维适形放疗治疗老年局部晚期非小细胞肺癌的临床观察朱江红,.局A-云,杨胜利,代军,何兴平(攀枝花市中心医院肿瘤科,四川攀枝花617067)中图分类号R734.2文献标志码A文章编号1001—0408(2014)32—3022—03DOI10.6039/j.issn.1001-0408.2014.32.16摘要目的:观察小剂量紫杉醇+顺铂(TP)方案联合三维适形放疗治疗老年局部晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法:46例老年局部晚期NSCLC患者均给予紫杉醇注射液150mg/m,静脉滴注,
2、d+顺铂注射液25mg/m,静脉滴注,也一+三维适形放疗照射肺部原发灶和肺门、纵膈淋巴结受累区,常规照射2Gy/次,5次/周,剂量这40Gy/20次后缩野,避开脊髓继续照射。总量达60~65Gy/30~33次,有锁骨上淋巴结转移者同时加野放疗。化疗前6、12h分别给予地塞米松i0mg,口服;化疗前0.5h给予甲氰咪胍0.4mg,静脉滴注;化疗前0.5h给予苯海拉明40mg,肌肉注射。3周为1个周期,至少2个周期后评价疗效及毒性反应,并随访生存率。结果:所有患者接受至少2个周期的治疗后总有效率为73.9%,疾病控制率为89
3、.1%。主要毒性反应为骨髓抑制,恶心、呕吐,放射性食管炎,放射性肺炎,但患者均可耐受。随访结束后14例生存,生存率为43.8%。结论:小剂量TP方案联合三维适形放疗治疗老年局部晚期NSCLC的疗效较显著,且安全性较好,可提高老年患者生存质量,但其远期疗效有待进一步观察。关键词非小细胞肺癌;紫杉醇;顺铂;三维适形放疗;老年ClinicalObservationofLow--doseTPCombinedwithThree·-dimensionalConformalRadiationTherapyintheTreatmento
4、fLocalAdvancedNon-smallCellLungCancerinElderlyPatientsZHUJiang—hong,GAOYun,YANGSheng—li,DAIJun,HEXing—ping(Dept.ofOncology,PanzhihuaMunicipalCentralHospital,SichuanPanzhihua617067,China)ABSTRACToBJECTIVE:Toobservetherapeuticeficacyandsafetyoflow—dosepaclitaxeland
5、cisplatin(TP)schemecom—binedwiththree.dimensionalconforlIlalradiationtherapyinthetreatmentoflocaladvancednon.smallcelllungcancer(NSCLC)inelderlypatients.METHODS:46elderlypatientswithadvancedNSCLCweregivenPaclitaxelinjection150mg/m2intravenously:combinedwjthCisp!a
6、tininjection25mg/mintravenouslydl:three.dimensionalconformalradiationtherapyd2in‘adiatingpulmo.flap/primarytumor.hilusoflung.mediastinallymphnodeinvolvementarea,2Gy/time,5timesaweek:reducedfieldandavoid.edmedullaspinalisafterdosereached40Gv/20time;theincreasefiel
7、dradiotherapywasconductedinpatientswithsuDraclavicuIar1ymphaticmetastasisaftertotaldosereached60—65Gy/30—33times.Theyweregivendexamethasone10mgorally6hand12hbeforechemotherapy.tagamet0.4mgintravenouslyO,5hbeforechemotherapy.anddimedrol40mgintramuscularly0.5hbefor
8、eche—motherapy.Atreatmentcourselastedfor3weeks.Therapeuticeficacyandtoxicreactionwereevaluatedandsurvivalratewasfol1owedupafteratleast2cycles.RESUIS:A11patient
此文档下载收益归作者所有